Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-06-01
2008-12-09
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S009100, C424S133100, C424S134100, C424S136100, C424S143100, C424S152100, C424S153100, C424S174100
Reexamination Certificate
active
07462352
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
REFERENCES:
patent: 5798554 (1998-08-01), Grimaldi et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6653104 (2003-11-01), Goldenberg
patent: 2003/0133930 (2003-07-01), Goldenberg
patent: WO 96/36360 (1996-11-01), None
patent: 0074718 (2000-12-01), None
Bataille et al. Haematologica Sep. 2006;91(9):1234-1240.
Matsushita et al. American Journal of Pathology 2006, 168;3:812-821.
Cochlovius, Bjorn, et al., “Treatment of Human B Cell Lymphoma Xenografts with a CD3 x CD19 Diabody and T Cells” the Journal of Immunology, 2000, 165: 888-895.
EK, Onur, et al., “Treatment of Human B-Cell Precursor Leukemia in SCID Mice by Using a Combination of the anti-CD19 Immunotoxin B43-PAP with the Standard Chemotherapeutic Drugs Vincristine, Methylprednisolone, and L-Asparaginase” Leukemia and Lymphoma, vol. 31, pp. 143-149.
Ghetie, Maria-Ana, et al., “Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin” Blood. 2001;97:1392-1398).
Ghetie, Maria-Ana, et al., “Evalution of Ricin A Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo therapy” Cancer Research 48, 2610-2617, 1988.
Ghetie, Maria-Ana, et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells” Proc. Natl. Acad. Sci. USA vol. 94, pp. 7509-7514, Jul. 1997.
Ghetie, Maria-Ana, et al., “The Antitumor Activity of an Anti-CD22 Immunotoxin in SCID Mice with Disseminated Daudi Lymphoma is Enhanced by Either an anti-CD19 Antibody or an Anti-CD19 Immunotoxin” Blood, vol. 80, No. 9 (Nov. 1), 1992: pp. 2315-2320.
Hekman, A., et al., “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody” Cancer Immunol Immunother (1991) 32: 364-372.
Ma, D., et al., “Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies” Leukemia (2002) 16, 60-66.
Mitchell, Paul, et al., “Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies” J Nucl Med 2003; 44:1105-1112.
Majolino, Patti, C., “High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas” European Journal of Haematology 1993: 51: 18-24.
Roguska, Michael A., et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing” Proc. Natl. Acad. Sci. USA vol. 91, pp. 969-973, Feb. 1994.
Rowland, A. J., et al., “Preclinical invesigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates” Cancer Immunol Immunother (1993) 37: 195-202.
Shan, Daming, et al., “Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells” Cancer Immunol Immunother (2000) 48:673-683.
Stone, Marvin J., et al., “A phase I Study of Bolus Versus Continuous Infusion of the anti-CD19 Immunotoxin, IgG-HD37-dgA, in Patients with B-Cell Lymphoma” Blood, vol. 88, No. 4 (Aug. 15, 1996, pp. 1188-1197.
Uckun, Fatih M., et al., “Treatment of Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia with an Apoptosis-inducing CD19-directed Tyrosine Kinase Inhibitor” Clincial Cancer Research vol. 5, 3906-3913, Dec. 1999.
Uckun, Fatih M., et al., “Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Potential of Anti-CD19 Immunotoxins” Blood, vol. 71, No. 1 (Jan. 1988; pp. 13-29.
Uckun, Fatih M., “Effective Immunochemotherapy of CALLA +Cu+ Human Pre-B Acute Lymphoblastic Leukemia in Mice with Severe Combined Immunodeficency Using B43 (anti-CD19) Pokeweed Antiviral Protein Immunotoxin Plus Cyclophosphamide” Blood, vol. 79, No. 12 (Jun. 15, 1992; pp. 3116-3129.
Zola, H., et al., “Preparation and characterization of a chimeric CD19 monoclonal antibody” Immunology and Cell Biology (1991) 69, 411-422.
Pietersz, Geoffrey A., et al., “In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody” Cancer Immunol Immunother (1995) 41: 53-60.
Roguska, Michael A., et al., “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing” Protein Engineering vol. 9, No. 10, pp. 895-904, 1996.
Goldenberg David M.
Hansen Hans J.
Qu Zhengxing
Dahle Chun
Haddad Maher M.
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Methods of treatng B-cell diseases using humanized anti-CD19... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatng B-cell diseases using humanized anti-CD19..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatng B-cell diseases using humanized anti-CD19... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032247